8-KOther EventsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Nov 20, 2006)

Filed November 20, 2006For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report detailing the completion of its public offering of common stock. On November 17, 2006, the company announced through a press release that it successfully sold 7,600,000 shares of its common stock. This event signifies a material financing activity for the company, likely providing additional capital for research, development, and operational expansion. Investors should note that this filing primarily pertains to the successful execution of a capital raise. While the specific use of proceeds is not detailed in this 8-K, such an offering typically aims to strengthen the company's financial position to support its pipeline and strategic initiatives. Further details regarding the offering's terms and implications would likely be found in the accompanying press release (Exhibit 99.1) and subsequent financial reports.

Key Highlights

  • 1Regeneron Pharmaceuticals, Inc. successfully completed a public offering of common stock.
  • 2A total of 7,600,000 shares were offered.
  • 3The press release announcing the completion was dated November 17, 2006.
  • 4This 8-K filing primarily serves to report on this significant financing event.
  • 5The press release is furnished as Exhibit 99.1 to the filing.

Frequently Asked Questions

The main purpose of this 8-K filing was to formally report the completion of Regeneron's public offering of 7,600,000 shares of common stock, as announced in their press release dated November 17, 2006.

Regeneron Pharmaceuticals, Inc. offered a total of 7,600,000 shares of common stock in this public offering.

More details about the public offering, including its terms and potential implications, can be found in the press release dated November 17, 2006, which is furnished as Exhibit 99.1 to this Form 8-K filing.

This specific 8-K filing primarily announces the completion of the offering and does not detail the specific use of the proceeds. Information regarding the use of funds would typically be disclosed in subsequent financial reports or investor communications.